A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia
PHASE1CompletedINTERVENTIONAL
Enrollment
40
Participants
Timeline
Start Date
June 7, 2018
Primary Completion Date
March 29, 2019
Study Completion Date
March 29, 2019
Conditions
Schizophrenia
Interventions
DRUG
DSP-1349M
DSP-1349M injectable
DRUG
placebo
placebo injection
Trial Locations (1)
90806
Dr. David Walling, Long Beach
All Listed Sponsors
lead
Sumitomo Pharma America, Inc.
INDUSTRY
NCT03627195 - A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia | Biotech Hunter | Biotech Hunter